Recently, a number of phage therapy phase I and II safety trials have been concluded, showing no notable safety concerns associated with the use of phage. Though hurdles for efficient treatment remain, these trials hold promise for future phase III clinical trials. Interestingly, most phage formulations used in these clinical trials are straightforward phage suspensions, and not much research has focused on the processing of phage cocktails in specific pharmaceutical dosage forms. Additional research on formulation strategies and the stability of phage-based drugs will be of key importance, especially with phage therapy advancing toward phase III clinical trials.

中文翻译：

---

噬菌体治疗：制定策略和人类临床试验的进展。

最近，已经完成了许多噬菌体治疗的I和II期安全性试验，显示与噬菌体的使用没有明显的安全隐患。尽管仍然存在有效治疗的障碍，但这些试验有望在未来的III期临床试验中发挥作用。有趣的是，在这些临床试验中使用的大多数噬菌体制剂是直接的噬菌体悬浮液，并且没有太多的研究集中在特定药物剂型的噬菌体混合物的加工上。关于噬菌体基药物的配制策略和稳定性的其他研究将至关重要，尤其是随着噬菌体治疗迈向III期临床试验。